• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Innovent Biologics Inc (OP: IVBXF )

    4.568 UNCHANGED
    Streaming Delayed Price Updated: 1:59 PM EDT, Oct 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 50
    Open 4.568
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 4.568
    Today's Range 4.568 - 4.568
    52wk Range 3.830 - 6.410
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
    Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with... 
    Via Talk Markets
    Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
    Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
    Via Talk Markets

    Performance

    YTD
    -15.40%
    -15.40%
    1 Month
    -23.86%
    -23.86%
    3 Month
    -1.76%
    -1.76%
    6 Month
    -12.32%
    -12.32%
    1 Year
    -26.91%
    -26.91%

    More News

    Read More
    Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
    Via Talk Markets
    Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
    Via Talk Markets
    Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
    Via Talk Markets
    Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
    Via Talk Markets
    Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
    Via Talk Markets
    Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
    Via Talk Markets
    Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform
    Via Talk Markets
    Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
    Via Talk Markets
    Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
    Via Talk Markets
    Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
    Via Talk Markets
    Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
    Via Talk Markets
    Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
    Via Talk Markets
    Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion
    Via Talk Markets
    Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
    Via Talk Markets
    Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
    Via Talk Markets
    Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
    Via Talk Markets
    Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
    Via Talk Markets
    Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
    Via Talk Markets
    Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
    Via Talk Markets
    Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
    Via Talk Markets
    Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
    Via Talk Markets
    Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
    Via Talk Markets
    Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.